RM

Rachel McMullan

Associate Director, Medical Communications at GRAIL

Rachel McMullan, PhD has a diverse work experience in various roles within the medical and scientific fields. Rachel is currently employed at GRAIL, Inc. as the Associate Director of Medical Communications. Prior to this, they held the position of Scientific Director at SIMPSON Healthcare and also worked as an Associate Scientific Director at the same company. Rachel served as a Medical Content Strategist at MicroMass Communications, Inc. Rachel began their career as a Graduate Research Assistant at the University of North Carolina at Chapel Hill, where they gained expertise in genetics, complex traits, exercise, body composition, and mouse model development. Rachel has also worked as a Business Technology Development Intern at the North Carolina Biotechnology Center, evaluating life-science loan applicants and conducting market research. Rachel started their research career as a Post Bac Researcher at the University of Richmond, where they performed experiments on motor proteins' function during the cell cycle. Prior to that, they were a Research Intern at Pioneer Hi-Bred International Inc. Rachel has proven herself to be a strategic thinker with strong business development insights, as evidenced by their consultant projects, internship, and coursework at UNC Kenan-Flagler Business School. Overall, Rachel McMullan, PhD brings a wealth of experience in medical communications, scientific research, and business development to their current role at GRAIL, Inc.

Rachel McMullan, PhD, completed their education at the University of North Carolina at Chapel Hill, where they obtained a Doctor of Philosophy (Ph.D.) in Genetics. Rachel attended the University of Richmond for their undergraduate studies and graduated with a Bachelor's degree in Biology/Biological Sciences, General. Additionally, they obtained a certification as a Content Strategist from Lynda.com in April 2018.

Links

Timeline

  • Associate Director, Medical Communications

    July, 2021 - present

View in org chart